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Abstract 
Immune checkpoint blockade therapy has changed prognoses for many melanoma patients. 
However, immune responses that correlate with clinical progression of the disease are still poorly 
understood. To identify immune responses correlating with melanoma clinical evolution, we 
analyzed serum cytokines as well as circulating NK and T cell subpopulations from melanoma 
patients. The patients’ immune profiles suggested that melanoma progression leads to changes in 
peripheral blood NK and T cell subsets. Stage IV melanoma was characterized by an increased 
frequency of CCR7
+
CD56
bright
 NK cells as well as high serum concentrations of the CCR7-ligand 
CCL19. CCR7 expression and CCL19 secretion were also observed in melanoma cell lines. The 
CCR7
+
 melanoma cell subpopulation co-expressed PD-L1 and Galectin-9 and had stemness 
properties. Analysis  of melanoma-derived cancer stem cells (CSCs) showed high CCR7 
expression; these CSCs were efficiently recognized and killed by NK cells. An accumulation of 
CCR7
+
, PD-L1
+
 and Galectin-9
+
 melanoma cells in melanoma metastases was demonstrated ex 
vivo. Altogether, our data identify biomarkers that may mark a CCR7-driven metastatic melanoma 
pathway. 
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Introduction 
Immune checkpoint therapy has changed prognoses for many melanoma patients, increasing their 
overall survival (1,2). These successes in melanoma therapy have emphasized the role of the 
immune response in controlling tumor burden. Temporal cascades of gene mutations characterize 
the natural history of melanoma from the appearance of the early malignant nevus to its metastatic 
systemic spread (3). However, less is known regarding changes in the immune response as the 
disease progresses. Analysis of circulating T and NK cells during melanoma progression may 
identify prognostic biomarkers that could be assayed through patient liquid biopsies and mark 
disease progression. 
Most melanoma patients at diagnosis have already developed local or disseminated lymph node 
(LN) metastases, but do not have visceral metastases. Prognoses for melanoma patients with early 
stage disease (II, III) are more favorable than prognoses for patients with stage IV disease.   
Self-renewing cancer stem cells (CSCs) are thought to be responsible for metastatic spread (4-6). 
CSCs express chemokine receptors that are involved in CSC phenotype promotion and/or 
maintenance (7). 
NK cells, members of the Innate Lymphoid Cell group 1 (ILC1) family (8), are the most abundant 
ILC population found in circulating blood. NK cells are cytotoxic lymphocytes that have little 
effect on primary tumor lesions (9-11) but can control solid tumor metastatic spread (12). NK cell 
recognition of melanoma cells has been reported both in vitro and in vivo (13-15). Human NK 
cells are regulated by activating and inhibitory receptors. Activating receptors include NCRs 
(NKp30, NKp44 and NKp46), NKG2D and DNAM-1 that recognize stress inducible molecules 
expressed on the tumor cell surface. Inhibitory receptors are mainly HLA-class I recognizing 
KIRs that induce NK cell tolerance (16). In humans, circulating NK cells fall into two subsets, 
CD56
bright 
and CD56
dim 
NK cells (17). The proportions of the two subsets varies with anatomical 
localization (16). CD56
bright
 NK cells prevail in secondary lymphoid organs and uterus, produce 
cytokines and have low cytotoxic potential. CD56
dim
 NK cells are effector cells that lyse cancer 
and virus-infected cells. Moreover, CD56
dim
 NK cells derived from individuals previously 
exposed to pathogens, such as human cytomegalovirus (HCMV), may include “memory-like” NK 
cells (18). Unknown cofactors associated with HCMV infection may induce the onset of a fully 
mature NK cell subset that is characterized by expression of the inhibitory checkpoint protein PD-
1 (19). 
Much is known about the regulation of NK cell-mediated cytotoxicity (20). NK cells selectively 
recognize melanoma metastatic cell lines (14) derived from tumor infiltrated lymph nodes. We 
showed that the presence of CD57
+
KIR
+
CCR7
+
CD3
- 
NK cells in melanoma-infiltrated lymph 
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nodes exerts an autologous anti-melanoma cytotoxicity the frequency of such cells may predict 
patient survival (21). The NK cell subset repertoire provides a number of variables that are associated 
with melanoma patients’ response to anti immune checkpoint treatment with ipilimumab (22). We and 
others demonstrated that NK cells are able to control CSC mediated lung metastasis (23-25). To 
better elucidate the immune pathogenesis of melanoma, we here analyze circulating NK and T 
cells subpopulations, as defined by receptor expression, in the context of melanoma. We focused 
particularly on cell subsets expressing chemokine receptors that control cell migration and the 
cyto-chemokine serum environment. Our objective was to understand changes in the immune 
response associated with melanoma clinical evolution. Our investigations led to insights 
concerning the chemokine biology of melanoma cells, particularly a subpopulation of melanoma 
cells that are cancer stem cells. Altogether, our results suggest a role for the CCR7-CCL19 
pathway during melanoma progression, in that a subpopulation of tumor cells may exploit the 
immune system through chemokine signaling. 
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Materials and Methods 
Melanoma patients 
For the characterization of changes happening in T and NK cell compartments in melanoma patients 
during disease progression, 166 melanoma patients (42 stage III and 124 stage IV melanoma 
patients) were enrolled in Italy at the NCI Fondazione “G. Pascale” of Naples and 24 stage IV 
melanoma patients were recruited at the Oncology clinic Karolinska University Hospital, 
Stockholm, Sweden. For each patient cohort, Ethical Committees associated with NCI of Naples, 
and Karolinska University Hospital, Stockholm granted ethical permission. Written informed 
consent was obtained from all patients in accordance with the Declaration of Helsinki for the use of 
human biological samples for research purposes. Stage III melanoma patients did not receive any 
treatment at the time of the enrollment, whereas stage IV were naïve or had been subjected to 
different types of chemotherapy. For lymphocyte compartment analysis and functional assays, 
peripheral blood mononuclear cells (PBMCs) were isolated from 80 and 29 patients, respectively. 
Cytokine quantification was performed on 88 patients. 
PMBCs from 42 persons and sera from 9 persons, all sex- and age-matched healthy donors, were 
also isolated as controls at the Pugliese-Ciaccio Hospital and University Magna Graecia of 
Catanzaro, Catanzaro, Italy. The experiments were performed once per patient. 
 
Isolation of peripheral blood lymphocytes and NK cell tumor cell lines 
PBMCs from 80 melanoma patients and 42 healthy donors were isolated by Biocoll separating 
solution (Biochrom AG, Berlin, Germany) density gradient centrifugation. For functional 
experiments requiring NK cells, these cells were isolated from healthy donor PBMCs using human 
NK Cell Isolation Kit (Miltenyi Biotech, San Diego, CA, USA) according to manufacturer’s 
instructions. The purity of isolated NK cells was > 95%, as assayed by flow cytometry. 
 
Cell lines 
K562, Huh7, a2780, RKO and HDFa cell lines were obtained from ATCC in 2013 (RKO and 
K562), 2014 (Huh7), 2015 (HDFa) and 2016 (a2780). Melanoma cell lines were obtained, based on 
informed consent, from surgical melanoma specimens of patients admitted at the Fondazione 
IRCCS Istituto Nazionale dei Tumori, Milan (2009), Istituto Nazionale Tumori - IRCCS 
“Fondazione G. Pascale”, Naples (2018), and San Raffaele University Hospital, Milan (2013) 
(Supplementary Table S1). K562, a2780 and all the melanoma cell lines were cultured in RPMI 
1640 medium (Life Technology, Milan, Italy) supplemented with penicillin (100 IU/mL) and 
streptomycin (100mg/mL) and 10% FBS. Huh7 and RKO cell lines were cultured in DMEM 
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medium (Life Technology, Milan, Italy) supplemented with penicillin (100 IU/mL) and 
streptomycin (100mg/mL) and 10% FBS. HDFa cell line was cultured DMEM medium (Life 
Technology, Milan, Italy) supplemented with penicillin (100 IU/mL) and streptomycin (100mg/mL) 
and 20% FBS. For all experiments, cells were used within two weeks after thawing. 
Melanoma stem cell isolation from metastatic melanoma specimens and propagation was performed 
as previously described (26), in accordance with the ethical standards on human experimentation. 
Melanoma stem cells were constantly authenticated by using the short tandem repeat (STR) system 
(GlobalFilter STR Kit, Applied Biosystems, Foster City, CA, USA) followed by DNA sequencing 
(ABIPRISM 3130 genetic analyzer, Applied Biosystem). Cells, growing as multicellular spheres, 
were cultured in serum-free medium supplemented with epidermal growth factor (EGF, 20 ng/ml, 
PeproTech) and basic fibroblast growth factor (bFGF, 10 ng/ml, PeproTech), using ultra-low 
attachment flasks (Corning Incorporated, Corning, NY, USA). Melanoma stem cells were washed 
twice with PBS and cultured in attachment conditions in 10% FBS DMEM for at least 21 days to 
obtain sphere-derived adherent cells (SDAC).  
To exclude mycoplasma infection, cells were routinely analyzed by the MycoAlert PLUS 
Mycoplasma Detection Kit (Lonza, Basel, Switzerland). In order to assess the sphere-forming 
capacity of CSCs, 1,000 cells/ml were plated in ultra-low attachment flasks. After 10 days, spheres 
that reached ≥ 50 µm of diameter were counted. In order to assess the tumorigenic capacity of 
CSCs, a total of 25 x 10
3
 CSCs were suspended in serum-free medium 1:1 matrigel (BD 
Biosciences Pharmingen, San Diego, CA, USA) and subcutaneously injected into NOD/SCID mice. 
All the used cell lines were maintained in culture for no longer than 3 weeks and were not 
authenticated in the past year. 
 
Immunofluorescence staining 
Thawed PBMCs from metastatic melanoma patients and healthy donors, as well as fresh melanoma 
cells and CSCs, were subjected to immunofluorescence staining (Supplementary Table S2). The 
isotype-specific goat anti-mouse was from Southern Biotechnology (Birmingham, AL, USA). For 
NCR ligand detection, NKp30-Fc NKp46-Fc were obtained as previously described (27). After 
incubation, cells were washed twice with PBS 1X, resuspended in FACS Flow and acquired by 
FACS CANTO II, FACS ARIA I, Accuri C6 or a FACS Verse flow cytometer (BD Biosciences). 7 
AAD Staining Solution (BD Biosciences) was added before each acquisition to distinguish between 
dead and live cells. In all the experiments, isotype-matched controls were used to set up the 
negative values. Data were analyzed using Flow-Jo version 10, version 9.3.1 software analysis 
(Treestar US, Ashland, OR, USA) or FacsSuite software (BD Biosciences).  
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CD107a mobilization assay after K562 pulsing 
To quantify cell surface expression of CD107a, degranulation assays were performed. Thawed 
lymphocytes derived from 27 melanoma patients (4 stage III and 25 stage IV) and 18 healthy 
donors were cultured at 37°C in 5% CO2 in the presence of 8μL of PE-conjugated CD107a/IgG1 
antibody (BD Biosciences) in U-bottom 96-well plates. After 1 h, Brefeldin A (10μg/mL) (Sigma 
Aldrich, Saint Louis, MO, USA) was added for 3 hours of incubation. Cells were then collected, 
washed with PBS 1X and stained with anti-CD56APC and anti-CD3FITC (Miltenyi Biotec) and 
acquired as described above. 
 
NK and melanoma cell co-culture 
Resting NK cells were cocultured at 37 °C in 5% CO2 with melanoma cells at 5:1 ratio in flat 
bottom 12-well plates (Corning Incorporated, Midland, NY, USA) supplied with 1640 RPMI (Life 
Technology, Milan, Italy) supplemented with penicillin (100 IU/mL) and streptomycin (100mg/mL) 
and 10% FBS. After 4 hours, cells were collected, stained and acquired as described above.  
 
Cytotoxicity assays 
Based on a protocol described elsewhere (28), cytotoxic assays were performed using fluorescent 
5,6-carboxy-fluorescein-diacetate (CFDA). In brief, target cells were labeled with 150 μg/ml of 
CFDA-mixed isomers (Invitrogen) for 30 minutes and then incubated in 96-well U-bottom plates at 
37°C in a humidified 5% CO2 incubator for 4h with freshly purified allogenic NK effector cells at 
different effector:target (E:T) ratios. Target cell specific lysis was analyzed by flow cytometry 
(FACS CANTO II and FACS ARIA I, BD Biosciences) and calculated as: % of specific lysis = 
(CT-TE)/CT*100, where CT indicates target cells’ mean fluorescence in control tubes and TE 
indicates target cells’ mean fluorescence in tubes containing effector cells. Data were collected and 
analyzed as described above. 
 
Immunohistochemistry and Immunofluorescence staining 
Hematoxylin & eosin staining was performed on paraffin-embedded sections of patient-derived 
primary melanoma, relative metastasis and xenograft tumor tissues, according to manufacturer’s 
instructions. 
Immunofluorescence staining was performed on 5-μm-thick embedded sections of human 
melanoma tissues and on melanoma CSCs cytospinned on glass slides. Cells were fixed in 2% 
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paraformaldehyde for 20 minutes at 37°C. Slides were exposed overnight at 4°C to CD44 (BU75, 
mouse IgG2a,k Ancell), CD271 (C40-1457, mouse IgG1a,k BD), ABCB5 (N13, goat IgG, 
SantaCruz), CD166 (MOG/07, mouse IgG2a,k, Novocastra), CCR7 (goat, Abcam), PD-L1 (mouse 
IgG1, R&D System), Gal-9 (rabbit IgG1, Thermo Scientific) or isotype matched controls IgG2a 
(mouse monoclonal Ancell), IgG1k (mouse BD), IgG (goat ThermoFischer Sceintific). Primary 
antibodies were revealed using Alexa Fluor-488 anti-rabbit, mouse or goat secondary antibodies. 
Nuclei were counterstained with Toto-3 iodide (Molecular Probes). In patient-derived primary 
melanoma and metastasis tissues, melanoma cells were distinguished from lymphocytes on the 
basis of cell morphology and size. Hematoxylin and eosin staining was performed by incubating 
sections with hematoxylin for 2 min and eosin for 1 min. 
 
Microarray cytokine assay 
To quantify serum cytokines, samples of thawed sera from 112 patients and 9 healthy donors were 
analyzed using the biochip analyzer Evidence Investigator (Randox Labs, Crumlin, UK) and the 
“Cytokine Array I” kit (Randox, Crumlin, UK), for the simultaneous quantification of the following 
cytokines: interleukin-2 (IL2), IL4, IL6, IL8, IL10, IL1a, IL1b, vascular endothelial growth factor 
(VEGF), interferon-g (IFNg), monocyte chemotactic protein-1 (MCP1), tumor necrosis factor-a 
(TNF-a), Epidermal Growth Factor (EGF). ELISA kits following manufacturer’s instructions 
evaluated the concentrations of IL15, IL21, CCL19 and CCL21, in patients’ serum and supernatants 
obtained from melanoma cell lines and melanoma CSC cultures; R&D Systems, Minneapolis, MN, 
USA for IL15, BioVendor, Brno, Czech Republic for IL21 and Aviva Systems Biology, San Diego, 
CA, USA for CCL19 and CCL21. Chemokine secretion from melanoma cells was assessed by 
measuring CCL19 and CCL21 concentration in 10 different melanoma cell lines and 7 melanoma 
CSCs using ELISA kits following manufacturer’s instructions (Aviva Systems Biology). 
 
Statistical analysis 
Data obtained from multiple experiments were analyzed for statistical significance. Data from two 
related groups were analyzed using the paired Student’s t-test or Wilcoxon signed rank test for 
samples that were or were not normally distributed, respectively. Data from two unrelated groups 
were analyzed using unpaired Student’s t-test or Mann–Whitney test for samples that were or were 
not normally distributed, respectively. Data from three related groups were analyzed using a two-
way analysis of variance (ANOVA) followed by Bonferroni’s correction. Data from three unrelated 
groups were analyzed using one-way ANOVA followed by Bonferroni’s correction or Kruskal-
Wallis test followed by Dunn’s correction for samples that were or were not normally distributed, 
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respectively. p-values < 0.05 were considered statistically significant. Kaplan–Meier (KM) curves 
were used to compare the survival of patients below or above median CCL19 serum concentration. 
The log-rank test was used to compare the KM curves and calculate the p-value. Statistical 
computations were performed using the GraphPad Prism 5.0 software.  
 
Multivariate analysis 
SIMCA, version 14 (MKS Data Analytics Solutions, Umeå, Sweden) was applied for multivariate 
analysis (29). A total of 85 variables, including immune profile and biographical variables, was 
applied in the analysis. 
Orthogonal Projections to Latent Structures and Discriminant Analysis (OPLS-DA) was used to 
distinguish groups and identify parameters characterizing each group. As a development of classical 
principal component analysis, in OPLS-DA the systematic variation in the data is summarized into 
scores (T) that represent the systematic variation in the N-dimensional variable space related to a Y-
variable outcome. In this projection method, all the variations related to the separation between 
groups are present in the predictive component(s) t[x], while the variation unrelated to separation 
between groups is visualized as “orthogonal components” to [x]. The contribution of each variable 
to the phenotype of each group of samples is indicated by the regression coefficient, that ranges 
from -1 (perfect negative correlation) to +1 (perfect positive correlation). OPLS-DA model quality 
is assessed by internal cross-validation, and presented as the percentage of data explained and 
predicted by the models. A good biological model is defined as having > 40% predictive capacity. 
The model was built on the basis of excluding biologically irrelevant and/or redundant variables 
(i.e. subsets with no signal) and screening for outliers (samples deviating significantly both from 
their own group and the global OPLS-DA model).  
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Results 
Immune profiles of melanoma patients during disease progression 
To investigate the correlation between immune variables and melanoma progression, the immune 
profile of PBLs from 42 healthy donors and 80 melanoma patients, grouped according to TNM 
classification of the American Joint Committee on Cancer (AJCC) (30) (stage III, n = 15; stage IV, 
n = 65) was analyzed by flow cytometry. Patients at stage IV were analyzed in a previous study 
(22); those profiles were used here to compare with immune profiles obtained from patients at stage 
III. 
Data from the immune profiles, together with biographical variables (Supplementary Table S3), 
were used to create a multivariate model. Based on the Principal Component Analysis, Orthogonal 
Projections to Latent Structures Discriminant Analysis (OPLS-DA) evaluates all the variables 
simultaneously, giving them the same importance independent of the value range. This approach 
allows assessment and display of both the co-variation between variables and the correlation to a 
specific group of samples. Since the components are orthogonal, the difference between groups is 
represented by the first principal component (horizontal axis), whereas orthogonal components 
(vertical axis) stand for unrelated variation. Compared to traditional methods for statistical analysis, 
the advantage of using OPLS-DA models for biomarker identification is that a smaller cohort of 
patients is needed for the analysis. 
The OPLS-DA model was built including only samples characterized for at least 50% of the 
variables considered. Thus, 37 healthy donors, 11 stage III and 42 stage IV melanoma patients were 
included. The OPLS-DA model gave a good separation between healthy donors and the two groups 
of patients (Fig. 1A), explaining 79% of the difference between them with a cross-validated 
predictive capacity of 69%. Overall, 66 variables contributed to distinguishing the groups. The ten 
most significant variables characterizing each group as well as the relative contribution of each 
characterizing variable are reported in Figures 1B-D. 
The immune profile characteristic of healthy donor featured high frequency and expression of 
NKp46 on the CD56
dim
 NK cell compartment. The stage III immune profile was characterized by 
high frequencies of chemokine receptors (CXCR2, CCR2) and NK activating receptors (NKG2D, 
NKp30, NKG2C). Stage IV melanoma patients were characterized by elevated percentages of 
CCR7 and CXCR2 on NK cells and high expression of inhibitory receptors (Tim-3, PD-1) on both 
NK and T cells. 
Overall, the immune variables applied in the multivariate analysis identified separate groups and 
identified the variables best correlating with disease staging. Since the OPLS-DA identifies even 
those variables that are significant only when taken together with other parameters, variables 
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reported by the model were analyzed also in univariate mode to select biomarkers that remain 
significant even when considered on their own. The complete list of variables characterizing the 
immune profile of each group, together with the univariate validation, is reported in the 
Supplementary Table S4. 
 
Functional analysis of T and NK cells from melanoma patients 
The functional features of circulating NK and T cells at different disease stages were analyzed to 
understand their possible role in the pathophysiology of melanoma. Lymphocyte activation was 
investigated in a subset of patients. Representative plots for NK and T cells degranulation are 
showed in Figure 2A, B. NK cells from melanoma patients showed higher spontaneous 
degranulation compared to healthy donors (Fig. 2C). On the other hand, T cell degranulation was 
higher in stage IV melanoma patients compared to healthy donors (Fig. 2D). 
 
Changes in CCR7
+ 
CD56
bright
 NK cells and CCL19 mark disease evolution 
To characterize cytokine profiles, sera from stage III and stage IV melanoma patients were analyzed 
and compared. Most of the stage IV melanoma patients had been previously characterized (22). The 
univariate analysis showed significant differences between stage III and IV for 5 out of 15 
cytokines: CCL2, IL6, CXCL8, IL15 and CCL19. All the cytokines showed a steady longitudinal 
serum concentration increase paralleling melanoma disease clinical evolution. Since CCL2, CXCL8 
and CCL19 reached the highest concentration at stage IV, we analyzed expression of their cognate 
receptors on both NK and T cell subpopulations (Supplementary Table S4). Among them, only the 
percentage of CCR7 on the CD56
bright
 NK cell subset displayed a pattern similar to the respective 
chemokine (Fig. 3A-B). Indeed, the frequency of CCR7
+
CD56
bright
 NK cells reached its peak in 
stage IV melanoma patients, as did CCL19 concentration, suggesting an ectopic recruitment of this 
NK subset in the blood. Thus, this pathway may feature in melanoma progression. 
The increased of CCL19 in sera may depend on its production by melanoma cells. Indeed, 
melanoma can produce IL8 and MCP-1 (31-33). Thus, we speculated that the high CCL19 observed 
in stage IV melanoma patients could be due to ectopic production from melanoma cells. To test this 
hypothesis, we measured CCL19 concentrations in supernatants from primary and metastatic 
melanoma cells, melanoma cancer stem cells (CSCs), fibroblasts and other solid tumors (hepatic, 
ovarian and colon carcinoma) cells. We observed CCL19 secretion by melanoma cells (Fig. 3C).  
Patient serum concentrations of the other four cytokines are listed in Supplementary Table S5. 
Serum concentrations of CCL2 exceeded the physiological range in all melanoma stages, whereas 
concentrations of the other three cytokines (IL6, CXCL8, IL15) reached pathological levels only in 
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stage IV melanoma. We previously demonstrated that melanoma cells produced CCL2, IL6 and 
CXCL8 (21). These soluble factors were found in culture supernatants of infiltrated lymph nodes 
from melanoma patients and were able to induce CCR7 expression on CD56
bright
 NK cells (21). The 
IL15 cytokine induced phenotypic changes in NK cells from melanoma patients (22). 
 
Melanoma cells susceptible to NK cell cytotoxicity express CCR7 
CCR7 is a receptor involved in lymph node homing, and lymph nodes are the first anatomical sites 
vulnerable to melanoma metastatic spread. Therefore, we hypothesized that CCR7 could be 
ectopically expressed in melanoma metastatic cell lines, driving their lymph node metastatic 
colonization. Thus, we analyzed a panel of patient-derived melanoma cell lines for CCR7 
expression. We also analyzed other surface molecules key to NK-melanoma cell cytotoxic synapse 
formation, such as MICA/B, PVR, HLA-class I, PD-L1, and Galectin-9. We analyzed ten 
melanoma cell lines of different anatomical origins. CCR7 was always expressed by a small 
fraction (1-5%) of melanoma cells (Fig. 4A) that appears to be a specific subpopulation. Indeed, 
such CCR7
+
 melanoma cells co-expressed CCR7 with two immune checkpoints ligands, PD-L1 and 
Galectin-9 (Fig. 4A-B), recognized by PD-1 and Tim-3 on lymphocytes, respectively. 
Thus, in each of ten different melanoma lines, a small fraction of cells expresses a chemokine 
receptor known for lymph node homing and also expresses PD-L1 and Galectin-9 that could protect 
from T and NK cell cytotoxic attack. Other molecules involved in NK cell cytotoxic synapses were 
measured. We found that CCR7
+
 melanoma cells displayed low expression of MHC class I 
molecules and PVR, but high expression of NCR ligands (Fig. 4C). On the other hand, the 
activating ligands MICA/B and ULBP2, recognized by NKG2D, showed variable expression, being 
expressed on only four and six of the ten cell lines analyzed, respectively (Supplementary Fig. S1A-
B). The low MHC class I and the high NCR ligands expression on CCR7
+
 melanoma cell surface 
suggested an increased susceptibility to NK cell cytotoxicity. 
To test whether NK cells could target CCR7
+
 melanoma cells, we performed cell co-cultures using 
melanoma cells lines and NK cells. After co-culture with fresh NK cells, a reduction in the 
frequency of CCR7
+
PD-L1
+
Galectin-9
+ 
(referred as CCR7
+
 cells) subpopulation was observed (Fig. 
4D, left panel), whereas the CCR7
- 
PD-L1
-
 Gal-9
-
 (referred as CCR7
-
 cells) melanoma cell 
population was not affected by NK cell exposure (Fig. 4D, right panel). Furthermore, CCR7
+
 
melanoma cells that survived after the NK cells co-culture were found to express higher HLA-class 
I molecules levels (Supplementary Fig. S1C). PD-L1 expression was not affected by NK cells 
exposure, thus, ruling out the possible effect of IFNγ produced by NK cells (34) in the induction of 
MHC-class I molecules on the resistant CCR7
+
 melanoma cells (Supplementary Fig. S1D). 
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CCR7 expression identifies melanoma CSCs susceptible to NK cell cytotoxicity 
CCR7
+
 melanoma cells are characterized by potentially higher migration capability, lower 
expression of membrane-associated MHC-class I molecules, low frequency within the bulk 
melanoma cell population, and increased susceptibility to NK cell-mediated killing. These features 
resemble those of CSCs (24, 35). To test the hypothesis that CCR7
+
 melanoma cells are CSCs, we 
compared CCR7
+
 cells to CSCs derived from melanoma generated with previously established 
methods (Table 1 and Fig. 5). First, we checked melanoma patient-derived CSCs for their ability to 
grow as spheres and to generate highly proliferating differentiated cells. We also tested for their 
aptitude to initiate tumor growth in immunocompromised mice (Fig. 5A-B). We showed that 
melanoma CSCs generated xenografts with histology typical of human melanomas (Fig. 5B). CSC 
stemness was confirmed by the expression of known stemness markers such as CD44, CD271, 
ABCB5 and CD166 (Fig. 5C and Supplementary Fig. S2A) (36-38). Finally, we measured the 
percentage of CSCs expressing CCR7 and observed that, in the four lines tested, CSCs 
homogenously expressed CCR7 (Fig 5D).  PD-L1 and Galectin-9 were also expressed on CSCs but 
to a different extent (Supplementary Fig. S2B). Thus, CCR7 expression seems to identify CSCs. 
Since we have previously demonstrated that human colon adenocarcinoma derived CSCs (25) and 
human and mouse breast adenocarcinoma CSCs (20) are susceptible to NK cell cytotoxic 
recognition, we evaluated melanoma CSC susceptibility to NK cell mediated lysis. Indeed, freshly 
purified NK cells showed an enhanced capability to recognize and kill melanoma-derived CSCs 
(Fig. 5E-G). 
To summarize, well-defined melanoma cancer stem cells share a number of characteristics with the 
melanoma subpopulations explored in this paper: expression of CCR7, PD-L1 and Gal-9 as well as 
high susceptibility to NK cells. Thus, we hypothesize that this melanoma cell population plays a 
role in metastasis. 
 
CCR7 is highly expressed in metastasis of melanoma patients 
We then evaluated the clinical relevance of CCR7, Gal-9 and PD-L1 in the process of metastasis 
dissemination and outgrowth. Immunohistochemical analysis on tissues derived from patients who 
have melanoma metastases revealed the enrichment of CCR7
+
 cells in melanoma metastatic lesions 
of the lymph node and parotid gland as compared to primary melanoma (Fig. 6A-C). Gal-9 and PD-
L1
+
 cells concomitantly expressed CCR7, suggesting that CCR7 is required for the metastatic 
outgrowth of aggressive melanoma cells (Fig. 6D). 
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We also analyzed the potential correlation between CCL19 serum concentrations and survival in a 
small cohort of patients. Our preliminary data (Supplementary Fig. S3) showed a tendency for a 
better overall survival in those patients who had less CCL19 in their blood; this observation needs 
to be validated in a larger patient cohort. 
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Discussion 
Immune profile analysis of melanoma patients at different stages of disease progression suggests 
that melanoma progression leads to changes in peripheral blood NK and T cell subsets. In stage III 
melanoma, the NK cell compartment is dominated by subpopulations expressing CXCR2 and 
CCR2, both of which are receptors for the melanoma-produced chemokines IL8 and CCL2 (MCP-
1), possibly indicating a more robust migration of NK cells in early-stage melanoma disease. 
Indeed, both IL8 and CCL2 act as a tumor autocrine growth factors increasing melanoma cell 
migration in metastatic lesions (39, 40). Thus, it is conceivable to speculate that these NK cell 
subsets may be able to migrate to the early melanoma metastatic foci. At this stage, circulating NK 
cell subsets expressing activating receptors (NKG2D, NKp30, NKG2C) prevail, whereas the T cell 
compartment is characterized by a reduced frequency of mature CD57
+
CD8
+
 cells associated with 
low levels of Tim-3 and CCR7. Circulating CD56
dim 
NK cells in stage III melanoma patients appear 
to be activated and display basal degranulation without any stimulation in vitro. Later in the 
disease’s evolution (stage IV), a similar feature is evident for T cells. This sequential activation, 
involving first the innate and then the adaptive immunity, recapitulates the physiological dynamics 
of the immune response. 
On the other hand, stage IV melanoma is characterized by an increased frequency and accumulation 
of CCR7
+ 
CD56
bright 
NK cells in patients’ blood. This phenomenon could be due to the cumulative 
effects exerted by CCL2, IL6 and IL8, as previously demonstrated (21), whose serum 
concentrations are increased in the latest stage of the disease. Serum at stage IV has higher 
concentrations of the CCR7-ligand CCL19 than serum at stage III. The ectopic presence of CCL19, 
otherwise characteristic of lymph nodes, could be part of a pathogenic mechanism interfering with 
NK cell migration in melanoma infiltrated lymph nodes. T cells expressing CCR7, in contrast with 
CD56
bright
 NK cells, did not increase in the blood of stage IV melanoma patients, suggesting that T 
cells may overcome the increased CCL19 sera concentration and redistribute to peripheral tissues. 
This could be explained by at least two, not mutually exclusive, mechanisms: (a) other lymph node 
homing receptors expressed by T cells, such as CD62L, could drive them to the lymph nodes 
independently of the CCR7-CCL19 axes, and (b) the cytokine milieu associated with stage IV 
melanoma (which includes IL6, CCL2 and IL8) does not induce CCR7 expression on T cells. 
Blood NK cells from stage III and IV melanoma patients showed increased expression of CD107a 
when explanted to in vitro culture without further stimulus. This spontaneous degranulation may 
reflect the recent in vivo activation of the cells (that the cells have been in action recently in vivo). 
CD107a expression might thus mimic a “smoking gun” following the NK cell attack on circulating 
melanoma cells. However, there are other possible explanations, such as generalized activation of 
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NK cells by cytokines and other factors associated with advanced disease. 
The scenario emerging from our study is that melanoma cells and related CSCs may produce 
CCL19, as described for cervical cancer (41). The increased serum concentration of CCL19 found 
in stage IV melanoma patients could be explained by the higher disease burden, where an increased 
number of CSCs actively secrete the chemokine. This could promote melanoma metastatic 
dissemination through at least two mechanisms: (1) CSCs migration from skin to blood circulation 
through the molecular combination between their CCR7 expression and the high patient’s CCL19 
blood concentration, (2) the high blood concentration of this chemokine, normally present only in 
the lymph nodes, retain CD56
bright
 NK cells in the blood and prevent their progression to the lymph 
nodes, reducing their frequencies in the melanoma infiltrated lymph nodes as we have previously 
demonstrated (21). However, it is also possible that CD56
bright 
NK cells resident in lymph nodes 
may be rerouted to the blood. Indeed, studies indicate that crosstalk between NK cells and DCs in 
the lymph nodes affects the CD8
+
 T cell anti-tumor immune response, as reviewed elsewhere (42, 
43). NK cells can edit the DC population (1) by physical elimination of immature DC or (2) by 
IFNγ production that induces full maturation of the DC skewing toward a Th1 immune response 
(44, 45). Thus, we speculate that the perturbation in CD56
bright 
NK cell migration in the lymph 
nodes may contribute to the failure of the anti-tumor immune response in the late stage of 
melanoma disease. Our data complement findings demonstrating that NK cell frequencies in 
melanoma tissues positively correlate with anti-PD-1 immunotherapy and overall survival (46). 
Regardless of the pathological meaning of CCL19 concetration and the accumulation of 
CCR7
+
CD56
bright
 NK cells in the blood circulation, our study demonstrates concomitant expression 
of CCR7 on melanoma CSCs and NK cells and that NK cells can recognize and eliminate 
melanoma CSCs that drive the disease’s metastatic spread. 
Ex vivo analysis showed that CCR7 is expressed more in metastatic melanoma cells than in 
melanoma cells at the primary tumor site. These data corroborate and expand previously reported 
findings (47, 48), suggesting that melanoma cells rely on CCR7 during metastasis. 
Moreover, Gal-9
+
 and PD-L1
+
 melanoma cells concurrently expressed CCR7 showing the presence 
of an aggressive subpopulation of CCR7
+
 cells endowed with immune evasion capabilities. Our 
results provide a foundation for developing melanoma therapies that could interfere with this 
metastatic pathway by the use of monoclonal antibodies targeting CCL19. 
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Sample Stage Type of melanoma 
metastasis 
Sphere forming Xenograft 
CSC#1 IV Unknown Yes Yes 
CSC#2 IV Lung Yes Yes 
CSC#3 IV Lung Yes Yes 
CSC#4 IV Lymph node Yes Yes 
Table 1. Case description and sphere forming/tumorigenic capacity of melanoma stem cells. 
 
Figure legends 
Figure 1. Discriminant analysis of healthy donors and melanoma patients. 
(A) Light grey dots = healthy donors (37), dark grey dots = stage III melanoma patients (11), black 
dots = stage IV melanoma patients (42). Horizontal axis = predictive component. Vertical axis = 
Orthogonal component not related to difference between groups. Ellipse = Hotelling’s T2 95 % 
confidence interval limit. (B-D) 10 most significant variables correlated to healthy donors, stage III 
and stage IV melanoma patients, respectively. Regression coefficient represents relative 
contribution magnitude of each variable. Error bars = 95 % confidence intervals. 
 
Figure 2. Analysis of NK and T cell function in healthy donors and melanoma patients. 
(A-B) Representative dot plots of CD107a degranulation by NK (A) and T cells (B) from healthy 
donor (left panels), stage III (middle panels) and stage IV (right panels) melanoma patients. (C-D) 
Statistical analysis of CD107a degranulation by NK (C) and T cells (D) obtained from 18 healthy 
donors (white bars), 4 stage III (grey bars) and 25 stage IV (black bars) melanoma patients. The 
assay was performed once per sample. Analyses were performed Kruskal-Wallis test followed by 
Dunn’s correction. ***p-value < 0.001; **p-value < 0.01. 
 
Figure 3. CCR7 and CCL19 in melanoma patients. 
(A-B) Circles = healthy donors; squares = stage III melanoma patients, triangles = stage IV 
melanoma patients. (A) Frequency of CCR7
+
CD56
bright
NK cells in 42 healthy donors, 15 stage III 
and 65 stage IV melanoma patients. Immunoprofile was performed once per sample. (B) Serum 
concentration of CCL19 in 9 healthy donors, 14 stage III and 22 stage IV melanoma patients. 
Measurement was performed in duplicate once per sample. (C) Mean CCL19 concentrations 
measured during the 48-120 hours timeframe in supernatants from fibroblast (circles, n = 1), solid 
tumor (squares, n = 3) primary and metastatic melanoma (diamonds, n =10; white indicate cells 
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derived from primary lesions, black diamonds indicate cells derived from metastatic lesions) and 
melanoma cancer stem cell lines (triangles, n = 7). Histological origin of melanoma cell lines is 
reported in Supplementary Table S1. For each time point, 3 independent experiments were 
performed in duplicate. Data are shown as mean ± SD. Analyses were performed by Kruskal-Wallis 
test followed by Dunn’s correction (A-C) or ANOVA followed by Bonferroni’s correction (B). 
***p-value < 0.001; # p-value ≤ 0.1  
 
Figure 4. NK-mediated targeting of CCR7
+ 
melanoma cells. 
(A) Representative plot of CCR7 frequency in melanoma cells and differential distribution of PD-
L1 and Galectin-9 in CCR7
-
 and CCR7
+
 melanoma cells. (B) Frequency of the indicated molecules 
on CCR7
-
 (white bars) and CCR7
+
 (black bars) melanoma cells. Data refer to 10 different cell lines, 
for each of which measures were repeated in three independent experiments. (C) Expression of the 
indicated molecules on CCR7
-
 (white bars) and CCR7
+
 (black bars) melanoma cells Data refer to 10 
different cell lines, for each of which measures were repeated in three independent experiments, and 
are shown as mean ± SD. The two melanoma cell subpopulations, CCR7
-
 and CCR7
+ 
cells, were 
gated as reported in panel A. For NKp30-L and NKp46-L detection, NKp30-Fc NKp46-Fc were 
used in indirect immunofluorescent stainings, whereas direct immunofluorescent staining was used 
to detect the other indicated molecules. Based on distribution, analysis was performed by Student’s 
paired t-test or Wilcoxon signed rank test. (D) Percentage of surviving CCR7
+ 
(left panel) and 
CCR7
-
 (right panel) melanoma cells before (white bars) and after (black bars) co-culture with 
circulating freshly purified allogenic NK cells. Data deriving from four independent experiments 
are shown as mean ± SD. Analysis was performed by paired Student’s t-test. ***p-value < 0.001; 
**p-value < 0.01; *p-value <0.05. 
 
Figure 5. Primary melanoma cells and CSC susceptibility to NK-mediated killing. 
(A) Sphere-derived adherent cells (SDAC) formation from melanoma stem cells. (B) Hematoxylin 
and eosin (H&E) staining, with respective magnification, of tumors generated by subcutaneous 
injection of patient-derived melanoma stem cells in NOD SCID immunocompromised mice. (C) 
Confocal microscopy analysis of the expression of stemness surface markers (CD44, CD271, 
ABCB5 and CD166) on primary melanoma-derived CSCs; the reported markers are labeled in 
green; nuclei are labeled in blue (Toto-3). (D) Frequency of CCR7
+
 cells within melanoma cells 
(white bar) and CSCs (black bar). Data deriving from 10 primary melanoma cells and 4 CSCs are 
shown. (E, F) Cytotoxicity assays performed by culturing primary melanoma cells (E) and CSCs 
(F) with circulating freshly purified allogeneic NK cells used at different E:T ratios, as reported on 
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the x-axis. (G) Statistical analysis of the data obtained from at least two independent cytotoxicity 
experiments for each tested cell line at two E:T ratios. Data are shown as mean ± SD. Analysis was 
performed by Mann-Whitney test; **p-value < 0.01, *p-value < 0.05. 
 
Figure 6. Metastatic melanoma cells express high amounts of CCR7. 
(A-C) Representative hematoxylin and eosin staining (Left panels) and immunofluorescence 
analysis of CCR7 (green color), Gal-9 (red color) and PD-L1 (red color) (Middle and Right panels) 
on paraffin-embedded sections of primary melanomas and relative metastasis. (A) Primary 
melanoma of the scalp and its micrometastasis to the mastoid lymph node, (B) frontoparietal 
melanoma and its metastasis to the parotid and (C) primary nasopharynx melanoma and its 
submandibular lymph node metastasis. Toto-3 (blue) stains the nuclei. White arrowheads indicate 
melanoma cells expressing both CCR7 and PD-L1 or CCR7 and Gal-9. Scale bar represents 40 µm. 
(D) Percentage of melanoma cells expressing CCR7, CCR7/Gal9 and CCR7/PD-L1 in primary 
melanomas and paired metastatic sites as described in (A-C). Data are shown as mean of 5 different 
fields counted for each sample ± SD. Analysis was performed by Mann–Whitney test; ***p-value < 
0.001. 
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